Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
Fiche publication
Date publication
janvier 2017
Journal
Journal of gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L
Lien Pubmed
Résumé
Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated.
Mots clés
Cost savings, Inflammatory bowel disease, Infliximab, Rheumatoid arthritis, Trough concentrations
Référence
J. Gastroenterol.. 2017 Jan;52(1):19-25